معرفی
Barbara Burtness, MD, is a Professor of Medicine (Medical Oncology) at Yale School of Medicine and holds leadership roles as Chief Translational Research Officer and Associate Cancer Center Director for Translational Research at Yale Cancer Center. She is Co-Leader of the Developmental Therapeutics Program and Division Chief for Head and Neck/Sarcoma Oncology. Her research focuses on targeted therapies and immunotherapy for head and neck cancers, with a focus on overcoming treatment resistance and improving patient outcomes.
Education & Training:
- MD, SUNY Stony Brook (1986)
- AB, Bryn Mawr College (1982)
- Residency & Internship: Yale-New Haven Hospital (1987–1989)
- Fellowship: Memorial Sloan Kettering Cancer Center (1993)
Research Interests: Dr. Burtness leads national and international trials in head and neck cancer, including studies of EGFR inhibition, synthetic lethality strategies, and aurora kinase A targeting. Her lab investigates novel therapeutic combinations for p53-mutated cancers and biomarkers of treatment resistance. Key areas include:
- Targeted therapies for EGFR-expressing cancers
- Immunotherapy strategies (e.g., pembrolizumab)
- Combination therapies to enhance responsiveness
Grants & Awards: Recipient of the Yale Cancer Center Clinical Science Prize and the Robert L. Krigel Award for Excellence in Teaching. Recognized as a Top Doctor by U.S. News and World Report.
Clinical Trials: Principal investigator on multiple trials, including studies evaluating dostarlimab, CUE-101, and pembrolizumab combinations. Active in ECOG-ACRIN Group trials.
Labs & Teams: Director of the Yale Head and Neck Specialized Program of Research Excellence (SPORE) and affiliated with the Yale Center for Immuno-Oncology.